The novel monoclonal protein, Pritoxaximab – formerly known as DXX00601 – presents considerable opportunity for the treatment of severe transfusion-related reaction (TRALI). Engineered by Bio-X, Pritoxaximab https://www.targetmol.com/compound/pritoxaximab